The phase II ALNEO trial (NCT05015010) investigating neoadjuvant alectinib in resectable stage III ALK-rearranged NSCLC is currently underway and expected to achieve completion in 2026 [76]. Here, ALK is linked to non-small cell lung carcinoma.